Antifungal Therapy Guidelines

Introduction to Antifungal Therapy

The choice of antifungal prophylaxis or treatment depends critically on the specific fungal pathogen suspected, the site of infection, and the patient's immune status—with voriconazole for invasive aspergillosis, fluconazole for most Candida infections, and amphotericin B for mucormycosis being the primary targeted therapies 1, 2, 3

High-risk surgical patients, neonates, and neutropenic patients with asymptomatic candiduria should be treated as disseminated candidiasis 1, 2

Amphotericin B deoxycholate (AmB-d) 0.7–1.0 mg/kg/day, voriconazole, itraconazole, echinocandins, or L-AmB 3 mg/kg/day are all acceptable options 1, 3
Use radiologic studies and laboratory markers (such as galactomannan antigen) rather than fever alone to stratify the likelihood of invasive fungal infection 1, 2

Favor amphotericin B deoxycholate for patients at risk of invasive zygomycosis (mucormycosis) 1, 2, 3
Favor voriconazole when radiological presentations are consistent with invasive aspergillosis along with positive galactomannan antigen 1, 2, 3

For candidemia without persistent fungemia or metastatic complications, treat for 3 weeks 4
AmB-d with or without flucytosine (5-FC); fluconazole 400–800 mg (6–12 mg/kg) daily for patients unable to tolerate AmB-d 1, 2, 5

Asymptomatic cystitis: therapy not usually needed unless high-risk surgical patients, neonates, or neutropenic patients 1, 2, 3, 6
Symptomatic cystitis: fluconazole 200 mg (3 mg/kg) daily for 14 days 1, 2, 3, 7, 6
Pyelonephritis: fluconazole 200–400 mg (3–6 mg/kg) daily for 14 days 1, 2, 3

Voriconazole, L-AmB, echinocandins, or itraconazole are options for pulmonary and extrapulmonary aspergillosis 1, 2, 3
Treatment should continue until resolution or stabilization of all clinical and radiographic manifestations 1, 2, 3

Liposomal amphotericin B is the drug of choice, with surgical resection of infected tissue being mandatory 5, 8
Aggressive surgical debridement is mandatory for optimal outcomes 5, 8

AmB-d plus flucytosine (5-FC) for 2 weeks for mild-to-moderate disease, followed by fluconazole for 10–12 weeks 3
Management of elevated intracranial pressure is critical: keep initial CSF opening pressure <200 mmH₂O 3

Dose adjustment of fluconazole may be necessary for patients with renal impairment 7
Candida isolated from lower respiratory tract does not require therapy; lower respiratory tract Candida infection is rare and requires histopathologic evidence to confirm diagnosis 1, 2, 3
Reversal of immunosuppression, if feasible, is important for favorable outcomes in invasive aspergillosis 1, 2, 3
Always consider species identification and susceptibility testing when selecting therapy, as resistance patterns vary significantly among Candida species 6